The differential sensitivity of human and rhesus macaque CCR5 to small-molecule inhibitors of human immunodeficiency virus type 1 entry is explained by a single amino acid difference and suggests a mechanism of action for these inhibitors
about
Analysis of the Macaca mulatta transcriptome and the sequence divergence between Macaca and humanCrystal Structures of HIV-1 gp120 Envelope Glycoprotein in Complex with NBD Analogues That Target the CD4-Binding Site"Resistance" to PSC-RANTES revisited: two mutations in human immunodeficiency virus type 1 HIV-1 SF162 or simian-human immunodeficiency virus SHIV SF162-p3 do not confer resistance.Analysis of binding sites for the new small-molecule CCR5 antagonist TAK-220 on human CCR5.Transmembrane protein aptamers that inhibit CCR5 expression and HIV coreceptor functionDualtropic CXCR6/CCR5 Simian Immunodeficiency Virus (SIV) Infection of Sooty Mangabey Primary Lymphocytes: Distinct Coreceptor Use in Natural versus Pathogenic Hosts of SIVNovel compounds containing multiple guanide groups that bind the HIV coreceptor CXCR4.A pièce de resistance: how HIV-1 escapes small molecule CCR5 inhibitors.One percent tenofovir applied topically to humanized BLT mice and used according to the CAPRISA 004 experimental design demonstrates partial protection from vaginal HIV infection, validating the BLT model for evaluation of new microbicide candidatesExpression of the chemokine receptor CCR5 in psoriasis and results of a randomized placebo controlled trial with a CCR5 inhibitorCCR5 antagonist TD-0680 uses a novel mechanism for enhanced potency against HIV-1 entry, cell-mediated infection, and a resistant variant.Cell surface expression of CCR5 and other host factors influence the inhibition of HIV-1 infection of human lymphocytes by CCR5 ligands.Transmitted/founder and chronic HIV-1 envelope proteins are distinguished by differential utilization of CCR5.Use of G-protein-coupled and -uncoupled CCR5 receptors by CCR5 inhibitor-resistant and -sensitive human immunodeficiency virus type 1 variants.Multifaceted mechanisms of HIV inhibition and resistance to CCR5 inhibitors PSC-RANTES and Maraviroc.Characterization of a human immunodeficiency virus type 1 V3 deletion mutation that confers resistance to CCR5 inhibitors and the ability to use aplaviroc-bound receptor.Escape from human immunodeficiency virus type 1 (HIV-1) entry inhibitors.Natural variation in the V3 crown of human immunodeficiency virus type 1 affects replicative fitness and entry inhibitor sensitivitySpecificity for a CCR5 Inhibitor Is Conferred by a Single Amino Acid Residue: ROLE OF ILE198.Ternary complex formation of human immunodeficiency virus type 1 Env, CD4, and chemokine receptor captured as an intermediate of membrane fusionHIV-1 clones resistant to a small molecule CCR5 inhibitor use the inhibitor-bound form of CCR5 for entry.Computational modeling of human coreceptor CCR5 antagonist as a HIV-1 entry inhibitor: using an integrated homology modeling, docking, and membrane molecular dynamics simulation analysis approach.
P2860
Q24812692-338DF248-659F-46E0-8DDA-A021DB1907D9Q27681568-FD100109-0E46-4635-ABB6-B9225B179ED7Q33877312-AF69FF9E-5754-49AF-A66A-6892292E4087Q34123627-2B1E8404-1382-42BA-B080-0319B4C9DC61Q34343448-7961871E-D4E2-4B16-B467-40299033B922Q34482304-BF1D7FD4-5249-4A69-A171-91674292FD50Q34483653-77F4592B-2907-4400-8537-D8F231FD2436Q34606129-97212888-036A-4CCD-82ED-8F2BBD3AEC08Q35140303-8253919D-0551-45CE-AF76-C4FB842D12DDQ35945026-4EF337CE-D9F3-4C79-8086-DB8E4A08605FQ35956560-DD7E7D9B-3510-4263-B46C-1A39B3BDADCAQ36296739-3A51EAFF-3148-4438-B896-63D330DF0EEDQ36607127-B9093D05-67D4-4E52-9B3E-B1496010F33FQ36911645-452B1BF7-25C3-4430-836F-1D80166E3BD2Q37026646-BECB4D62-6570-45B6-8774-EB67B8083056Q37145319-DE5B5160-A169-4E84-8BC9-F7E00EF2FAB7Q38076139-E1A43D8A-7AAE-4481-AAE3-8674DE9734D4Q39186710-A0CA4B67-F5D6-46CD-AF1A-C919187BCBFFQ39944975-2F475024-0DE8-4976-8203-D570E4EEC53AQ40384583-6A5D620E-4E41-412A-AD36-74C3121171EEQ41895256-5AE445CB-C21C-4C1A-98F6-E42E18F65179Q46477869-7B660D8E-AE12-4152-9874-9A21DAE69DD1
P2860
The differential sensitivity of human and rhesus macaque CCR5 to small-molecule inhibitors of human immunodeficiency virus type 1 entry is explained by a single amino acid difference and suggests a mechanism of action for these inhibitors
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on April 2004
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
The differential sensitivity o ...... of action for these inhibitors
@en
The differential sensitivity o ...... f action for these inhibitors.
@nl
type
label
The differential sensitivity o ...... of action for these inhibitors
@en
The differential sensitivity o ...... f action for these inhibitors.
@nl
prefLabel
The differential sensitivity o ...... of action for these inhibitors
@en
The differential sensitivity o ...... f action for these inhibitors.
@nl
P2093
P2860
P1433
P1476
The differential sensitivity o ...... of action for these inhibitors
@en
P2093
Bahige M Baroudy
Christoph Seibert
Elizabeth Coates
Erika Billick
Gregory R Reyes
John P Moore
Michael J Endres
Nicholas J Murgolo
Pavel Pugach
Shawn E Kuhmann
P2860
P304
P356
10.1128/JVI.78.8.4134-4144.2004
P407
P577
2004-04-01T00:00:00Z